AI 본문요약

엑셀 다운로드 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

참고문헌 (18)

1. Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., and Schneider, R. L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care, 23, 1605-1611(2000) 

   상세보기

2. Berger, J. and Moller, D. E., The mechanisms of action of PPARs. Ann. Rev. Med., 53, 409-435 (2002) 

   상세보기

3. Cantello, B. C., Cawthorne, M. A., Cottam, G. P., Duff, P. T., Haigh, D., Hindley, R. M., Lister, C. A., Snith, S. A., and Thurlby P. L., [[Omega-(heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 37, 3977-3985 (1994) 

   상세보기

4. Dahl-Jorgensen, K. and Brinchmann-Hansen, O., Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br. Med.J., 293, 1195-1199 (1986) 

   상세보기

5. Defronzo, R. A., Bonadonna, R. C., and Ferrannini, E., Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 15, 318-368 (1992) 

   상세보기

6. Defronzo, R. A., Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes, 37, 667-687 (1988) 

   상세보기

7. Desvergne, B. and Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endcrine Rev., 20, 649-688 (1999) 

   상세보기

8. Feldt-Rasmussen, B., Mathisesn, E., and Deckert, T., Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet, 2, 1300-1304 (1986) 

9. Holman, R. R. and Turner, R. C., Textbook of Diabetes; Pickup, J. C., Williams, G. Eds.; Blackwell Scientofic Publications: London, pp 462-476 (1991) 

10. Ibrahimi, A., Teboul, L., Gaillard, D., Amir, E. Z., Ailhaud, G., Young, P., Cawthorne, M. A., and Grimardi, P. A., Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol., 46, 1070-1076 (1994) 

    상세보기

11. Kersten, S., Desvergne, B., and Wahli, W., Roles of PPARs in health and disease. Nature, 405, 421-424 (2000) 

    상세보기

12. Kletzien, R. F., Clark, S. D., and Ulrich, R. G., Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol., 41, 393-398 (1992) 

    상세보기

13. Lehmann, J. M., Moorre, L. B., Smith-Oliver,T A, Wilkinson, W. O., Wilson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956 (1995) 

    상세보기

14. Martin, G., Schoonjans, K., Staels, B., and Aurex, J., $PPAR{\gamma}$ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atheroscrelosis, 137 (Suppl), S75-S80 (1998) 

    상세보기

15. Morita, H., Mori, H., and Kobayashi, Y., Process for the production of a thiazolidine derivative. GB 2324089A (1998) 

16. Ruderman, N. B. and Scheneider, S. H., Diabetes, exercise, and atherosclerosis. Diabetes Care, 15 (Suppl. 4), 1787-1793 (1992) 

    상세보기

17. Sohda, T., Momose, Y., Meguro, K., Kawamatsu, Y., Sugiyama, Y., and Ikeda, H., Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneim.-Forsch., 40, 37-42 (1990) 

18. Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y., Kurumada, T., Hasegawa, K., and Horikoshi, H., Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem., 32,421-428 (1989) 

    상세보기